In our multicenter series of patients with PBMC, when we investigated factors related to outcome, the best results correlated with a lengthy interval between BC and PBMC onset, positive HR status, possible treatment with HER2-targeted agents, and with PM as the only metastatic location. Here, ERBB2 is linked to breast cancer.